Canaccord Genuity Maintains Buy on Passage Bio, Lowers Price Target to $67
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $260 to $67.
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and lowers the price target from $260 to $67.